Evidence map›Paper›PMID 32239145›Full record

ArticleJournal of the National Cancer Institute2021

Physical Activity Before, During, and After Chemotherapy for High-Risk Breast Cancer: Relationships With Survival.

Rikki A Cannioto, Alan Hutson, Shruti Dighe, William McCann, Susan E McCann, Gary R Zirpoli, William Barlow, Kara M Kelly, Carol A DeNysschen, Dawn L Hershman and 11 more

Registry-linked trialOpen access · bronzeAbstract read
In one paragraph

Article in Journal of the National Cancer Institute, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07107594 (Multimodal Intervention During Neoadjuvant Chemotherapy in Patients With Early-breast Cancer as a Strategy to Improve Treatment Response), which is not on this map. Cited by 121 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
121citing papers in PubMed, 7 pooled it
9.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07107594 narecruitingnot on this mapstarted 2025, after this paper: background citation

Multimodal Intervention During Neoadjuvant Chemotherapy in Patients With Early-breast Cancer as a Strategy to Improve Treatment Response: DIANA Trial (Multimodal Prehabilitation: DIet, ANxiety Control Psychotherapy, Physical Activity)

TypeinterventionalSponsorHospital Clinic of BarcelonaRan2025 to 2028Enrolled214ConditionsBreast Cancer Early Stage Breast Cancer (Stage 1-3), PrehabilitationArmsMultimodal prehabilitation
3 · Its place in the literature

Who cites it

121 citing papers in PubMed, 7 syntheses or guidelines pooled it, 182 citations in OpenAlex.

  1. Pooled it
  2. The Effects of Post-diagnosis Recreational Aerobic Exercise among Breast Cancer Survivors: A Systematic Review/Meta-Analysis.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2025
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Factors associated with programme completion and physical activity adherence in a community-based cancer exercise programme.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
    Article
  18. Review
  19. Article
  20. Article

61 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 11 institutions in 1 country.

Rikki A CanniotoDepartment of Cancer Prevention and Control, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
Alan HutsonDepartment of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
Shruti DigheDepartment of Cancer Prevention and Control, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
William McCannDepartment of Cancer Prevention and Control, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
Susan E McCannDepartment of Cancer Prevention and Control, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
Gary R ZirpoliSlone Epidemiology Center, Boston University, Boston, MA, USA.
William BarlowSWOG Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Kara M KellyDepartment of Pediatric Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
Carol A DeNysschenDepartment of Cancer Prevention and Control, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
Dawn L HershmanDepartment of Medicine, Columbia University, New York, NY, USA.
Joseph M UngerSWOG Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Halle C F MooreDepartment of Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
James A StewartDepartment of Hematology and Oncology, Baystate Medical Center, Springfield, MA, USA.
Claudine IsaacsFisher Center for Hereditary Cancer and Clinical Genomics Research, Georgetown University, Washington, DC, USA.
Timothy J HobdayDepartment of Medical Oncology, Cancer Center, Mayo Clinic, Rochester, MN, USA.
Muhammad SalimMedical Oncology, Allan Blair Cancer Centre, Regina, SK, Canada.
Gabriel N HortobagyiDepartment of Breast Medical Oncology, Division of Cancer Medicine - Clinical, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Julie R GralowBreast Medical Oncology, Seattle Cancer Care Alliance, Seattle, WA, USA.
Kathy S AlbainDepartment of Medicine, Loyola University Chicago Stritch School of Medicine, Chicago, IL, USA.
G Thomas BuddDepartment of Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
Christine B AmbrosoneDepartment of Cancer Prevention and Control, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
Roswell Park Comprehensive Cancer Center · USCleveland Clinic · USFred Hutch Cancer Center · USBaystate Medical Center · USBoston University · USColumbia University · USGeorgetown University · USLoyola University Chicago · USMayo Clinic in Arizona · USSeattle Cancer Care Alliance · USThe University of Texas MD Anderson Cancer Center · US

Funding

SWOG Network Group Operations Center of the NCTNU10CA180888 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI PRIMO N. LARA · 2014 to 2026
$152.1M
Two-Spirit Films in Indigenous Cancer HealthP30CA016056 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI Dean G. Tang · 1985 to 2026
$116.6M
SWOG Statistics & Data Management Center complex - extension supplement for GY06U10CA180819 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Catherine M. Tangen · 2014 to 2026
$115.2M
SWOG NCORP Research BaseUG1CA189974 · NCI · THE HOPE FOUNDATION · PI CHARLES D. BLANKE, DAWN HERSHMAN · 2014 to 2026
$80.6M
NCIC Clinical Trials Group - Canadian Collaborating Clinical Trials NetworkU10CA180863 · NCI · QUEEN'S UNIVERSITY AT KINGSTON · PI Janet Ellen Dancey · 2014 to 2026
$40.4M
UT MD Anderson Cancer Center Network Lead Academic Participating Site (LAP)U10CA180858 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI HUNT, KELLY K, PINNIX, CHELSEA CAMILLE · 2014 to 2018
$5.6M
SWOG GRANT APPLICATION FOR LOYOLA UNIVERSITYU10CA046282 · NCI · LOYOLA UNIVERSITY CHICAGO · PI STIFF, PATRICK J · 1988 to 2013
$5.4M
SOUTHWEST ONCOLOGY GROUP CA13612U10CA013612 · NCI · UNIVERSITY OF ARIZONA · PI CRANMER, LEE D · 1985 to 2013
$4.5M
UM LAPs- U10 GrantU10CA180801 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI ZALUPSKI, MARK M · 2014 to 2018
$3.7M
Hutchinson Center as Lead Academic Participating Site (U10)U10CA180828 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI APPELBAUM, FREDERICK · 2014 to 2018
$3.0M
Genome-Wide Predictors of Treatment-Related ToxicitiesR01CA139426 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI AMBROSONE, CHRISTINE B. · 2011 to 2013
$2.8M
Antioxidant supplements, genetics, and chemotherapy outcomesR01CA116395 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI AMBROSONE, CHRISTINE B. · 2006 to 2009
$2.4M
NCI NIH HHS N01 CA004919NCI NIH HHS N01 CA013612NCI NIH HHS P30 CA016056NCI NIH HHS R01 CA116395NCI NIH HHS R01 CA139426NCI NIH HHS U10 CA004919NCI NIH HHS U10 CA013612NCI NIH HHS U10 CA046282NCI NIH HHS U10 CA068183NCI NIH HHS U10 CA180801NCI NIH HHS U10 CA180819NCI NIH HHS U10 CA180828NCI NIH HHS U10 CA180858NCI NIH HHS U10 CA180863NCI NIH HHS U10 CA180888NCI NIH HHS UG1 CA189974
6 · The paper itself

Abstract

backgroundAlthough physical activity has been consistently associated with reduced breast cancer mortality, evidence is largely based on data collected at one occasion. We examined how pre- and postdiagnosis physical activity was associated with survival outcomes in high-risk breast cancer patients.

methodsIncluded were 1340 patients enrolled in the Diet, Exercise, Lifestyle and Cancer Prognosis (DELCaP) Study, a prospective study of lifestyle and prognosis ancillary to a SWOG clinical trial (S0221). Activity before diagnosis, during treatment, and at 1- and 2-year intervals after enrollment was collected. Patients were categorized according to the Physical Activity Guidelines for Americans as meeting the minimum guidelines (yes/no) and incrementally as inactive, low active, moderately active (meeting the guidelines), or high active.

resultsIn joint-exposure analyses, patients meeting the guidelines before and 1 year after diagnosis experienced statistically significant reductions in hazards of recurrence (hazard ratio [HR] = 0.59, 95% confidence interval [CI] = 0.42 to 0.82) and mortality (HR = 0.51, 95% CI = 0.34-0.77); associations were stronger at 2-year follow-up for recurrence (HR = 0.45, 95% CI = 0.31 to 0.65) and mortality (HR = 0.32, 95% CI = 0.19 to 0.52). In time-dependent analyses, factoring in activity from all time points, we observed striking associations with mortality for low- (HR = 0.41, 95% CI = 0.24 to 0.68), moderate- (HR = 0.42, 95% CI = 0.23 to 0.76), and high-active patients (HR = 0.31, 95% CI = 0.18 to 0.53).

conclusionsMeeting the minimum guidelines for physical activity both before diagnosis and after treatment appears to be associated with statistically significantly reduced hazards of recurrence and mortality among breast cancer patients. When considering activity from all time points, including during treatment, lower volumes of regular activity were associated with similar overall survival advantages as meeting and exceeding the guidelines.

Indexed as

Drug TherapyExerciseAgedBreastBreast NeoplasmsCombined Modality TherapyDisease-Free SurvivalFemaleHumansMiddle AgedNeoplasm Recurrence, LocalPrognosisProportional Hazards ModelsProspective StudiesRisk Factors

Identifiers

PMID32239145
PMCPMC7781460
OpenAlexW3014124313

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.